Richard E. Gilbert

MD, FRCPC, FRACP, FACP, FASN, PhD

Scientist, Keenan Research Centre for Biomedical Science

Biography

Richard Gilbert is Professor of Medicine at the University of Toronto, Canada Research Chair in Diabetes Complications and Head of the Division of Endocrinology at St. Michael’s Hospital in Toronto. His major interests are in the treatment and prevention of diabetic complications with an emphasis on nephropathy and heart failure. Dr. Gilbert has published over 220 peer-reviewed manuscripts, has numerous patents and co-founded Fibrotech, a biotechnology company that has brought novel anti-fibrotic therapies from the bench to early phase human trials. He is currently a member of the editorial board of Diabetes. Current research projects relate to the use of new therapies for the prevention and treatment of chronic kidney disease and heart failure. In addition to his bench research, Dr. Gilbert is actively involved in teaching and knowledge translation. He currently heads Guidelines Committees for the management of hypertension in diabetes.

Recent Publications

  1. Papademetriou, V, Nylen, ES, Doumas, M, Probstfield, J, Mann, JFE, Gilbert, RE et al.. Chronic Kidney Disease, Basal Insulin Glargine and Health Outcomes in People with Dysglycemia: the ORIGIN Study. Am. J. Med. 2017; :. doi: 10.1016/j.amjmed.2017.05.047. PubMed PMID:28842165 .
  2. Leung, AA, Daskalopoulou, SS, Dasgupta, K, McBrien, K, Butalia, S, Zarnke, KB et al.. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. 2017;33 (5):557-576. doi: 10.1016/j.cjca.2017.03.005. PubMed PMID:28449828 .
  3. Gilbert, RE. Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. Diabetes. 2017;66 (4):791-800. doi: 10.2337/db16-0796. PubMed PMID:28325740 .
  4. Gilbert, RE, Mende, C, Vijapurkar, U, Sha, S, Davies, MJ, Desai, M et al.. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther. 2017;8 (2):451-458. doi: 10.1007/s13300-017-0232-0. PubMed PMID:28197834 PubMed Central PMC5380494.
  5. Gilbert, RE. Finerenone in diabetic kidney disease - So far, so good. J. Diabetes Complicat. 2017;31 (4):651-652. doi: 10.1016/j.jdiacomp.2016.12.012. PubMed PMID:28153675 .
  6. Zhang, Y, Connelly, KA, Thai, K, Wu, X, Kapus, A, Kepecs, D et al.. Sirtuin 1 Activation Reduces Transforming Growth Factor-β1-Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. Am. J. Pathol. 2017;187 (1):80-90. doi: 10.1016/j.ajpath.2016.09.016. PubMed PMID:27993241 .
  7. Gilbert, RE. SGLT2 inhibitors: β blockers for the kidney?. Lancet Diabetes Endocrinol. 2016;4 (10):814. doi: 10.1016/S2213-8587(16)30237-6. PubMed PMID:27663956 .
  8. Leung, AA, Nerenberg, K, Daskalopoulou, SS, McBrien, K, Zarnke, KB, Dasgupta, K et al.. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2016;32 (5):569-88. doi: 10.1016/j.cjca.2016.02.066. PubMed PMID:27118291 .
  9. Gilbert, RE, Weir, MR, Fioretto, P, Law, G, Desai, M, Kline, I et al.. Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Can J Diabetes. 2016;40 (3):247-57. doi: 10.1016/j.jcjd.2015.11.005. PubMed PMID:27052454 .
  10. Yuen, DA, Huang, YW, Liu, GY, Patel, S, Fang, F, Zhou, J et al.. Recombinant N-Terminal Slit2 Inhibits TGF-β-Induced Fibroblast Activation and Renal Fibrosis. J. Am. Soc. Nephrol. 2016;27 (9):2609-15. doi: 10.1681/ASN.2015040356. PubMed PMID:26869008 PubMed Central PMC5004640.
Search PubMed

Affiliations & Other Activities

  • Professor, Medicine/Endocrinology, St. Michael’s Hospital, University of Toronto
X